Background: Cardiac troponin I (cTnI) results vary 100-fold among assays. As a step toward standardization, we examined the performance of 10 candidate reference materials (cRMs) in dilution studies with 13 cTnI measurement systems. Methods: Solutions of 10 cTnI cRMs, each characterized by NIST, were shipped to the manufacturers of 13 cTnI measurement systems. Manufacturers used their respective diluents to prepare each cRM in cTnI concentrations of 1, 10, 25, and 50 g/L. For the purpose of ranking the cRMs, the deviation of each cTnI measurement from the expected response was assessed after normalization with the 10 g/L cTnI solution. Normalized deviations were examined in five formats. Parameters from linear regression analysis of the measured cTnI vs expected values were also used to rank performance of the cRMs. Results: The three cRMs demonstrating the best overall rankings were complexes of troponins C, I, and T. The
cation of acute coronary syndrome patients (5, 6 ) , and guidance of therapeutic intervention (7) (8) (9) . For cTnT measurement, there have been three generations of quantitative assays and two generations of whole-blood qualitative tests. Assay harmonization has been achieved among these several cTnT assay formats because all cTnT assays have been produced by a single manufacturer (Roche Diagnostics). As a result, standardization of cTnT measurements is not currently an issue within the laboratory community. cTnI assays, on the other hand, present a somewhat different situation.
There are numerous cTnI assays that have been developed and marketed by various manufacturers. This has led to a situation where cTnI measurements using different methods on identical specimens may differ by 100-fold (10 ) , creating a substantive problem for the clinical and laboratory communities, particularly as the use of cTnI measurements increases. To help address this situation, the AACC formed a cTnI Standardization Committee in cooperation with NIST and in collaboration with the Standardization of Markers of Cardiac Damage Committee of the IFCC. The goal of the cTnI Standardization Committee is the designation of international reference materials for cTnI that will substantially reduce intermethod variation.
The use of candidate reference materials (cRMs) in standardization of cTnI assays may be complicated because release of this protein after myocardial injury is not yet completely understood. cTnI may be released predominantly as a troponin C-troponin I (CI) protein complex (11 ) , in part as free cTnI (12 ) or as a combination of these forms (13 ) , and as degradation products of the free cTnI subunit (13 ) . In addition, cTnI and the complex may be undergoing posttranslational changes after release, such as oxidation, phosphorylation, and proteolysis (14 ) . Further complicating standardization activities are the effects of lyophilization and reconstitution of reference materials and the need to demonstrate the commutability of measurements using a cRM from an artificial matrix to a physiologic one.
The primary objective of this report is to describe the efforts of the AACC cTnI Committee to select a feasible number of cRMs from among 10 that were characterized by NIST (unpublished data). This selection consisted of ranking the cRMs to identify those showing the best performance (i.e., most consistent and predictable analytic response), using 13 cTnI assay systems as measurement tools. In addition, the activities described here were intended to assist in developing reasonable expectations and directing further phases of cTnI standardization and harmonization.
Materials and Methods cRMs
The 10 materials listed in Table 1 were characterized by NIST for composition, purity, and approximate cTnI concentration (unpublished data). After characterization, each cRM was reconstituted or diluted in distilled water at NIST to contain cTnI in an estimated concentration of 50 mg/L and was stored at Ϫ70°C. Vials containing each reconstituted cRM were shipped to manufacturers for dilution, using each respective recommended diluent, and measurement.
cTnI methods
The cTnI systems used as measurement tools in this study are listed in Table 2 .
measurement protocol
Upon receipt, the 10 cTnI cRMs were maintained at Ϫ70°C until measurement, which occurred within 30 days. For studies in phase I, all dilutions of the cRMs were prepared in the diluent recommended by the manufacturer. Details of the cRM dilution scheme may be obtained as a data supplement to this article at Clinical Chemistry Online (http://www.clinchem.org/content/vol47/issue3). Briefly, aliquots of each of the 10 cRMs were prepared from the 50 mg/L cRM to produce 1.0-mL solutions with estimated cTnI concentrations of 1, 10, 25, and 50 g/L, using a 1000 g/L intermediate working solution. Manufacturers were directed to analyze these solutions in duplicate with their respective analytical systems immediately after preparation. Both replicate measurements were reported to the AACC cTnI Committee. 
data analysis
The rationale for assessing consistency and predictability of the cRMs was to normalize the response of cTnI assays for serial dilutions of each material. The deviation of the measured normalized response from the expected response was then calculated. The magnitude of the deviation (measured vs expected) reflected the consistency and predictability of each cRM, allowing ranking of the materials. In addition, cTnI systems use different calibrators; therefore, it was expected that part of this deviation was attributed to calibration differences. To take this into account, linear regression was performed in which the measured results were the dependent variable and the expected value was the independent variable. Several formats of absolute deviation analysis (see below) were used. Although the formats were not strictly independent, they provided a means to rank the cRMs under different constraints. Where linear regression analyses were used, random and systemic errors were assessed. The lower the random error for a cRM, the better the ranking. All analyses reported here were performed by individuals who were unaware of the identity of the various cRMs used in the phase I studies.
Absolute deviation. The intended purpose of this set of analyses was to evaluate the overall response of the cTnI systems to each cRM in a linear series of concentrations. For this purpose, results for the 10 g/L solution were used to normalize cRM response for the 1, 25, and 50 g/L solutions for each of the cTnI systems. The 10 g/L solution was used for normalization because this concentration was within the dynamic range of all assay systems and it was expected to have the lowest CV across the assay range. The ideal recovery of each cRM, i.e., the recovery if there was a perfect match between expected and measured at each concentration, was 1.00. The absolute deviation of the measured value from the expected result of 1.00 for each concentration was calculated for each cRM with each cTnI method, according to the following:
The mean absolute deviation within a cTnI method was a unitless quantity that was calculated according to the following:
Mean absolute deviation ϭ Խ 1 Ϫ (recovery of each solution) Խ
Number of solutions
Absolute deviation data were examined in five formats in an effort to avoid possible bias. The first format included data for all cTnI systems participating in the study in which results for at least three of the four cTnI concentrations were within the dynamic range of the assay. In the second format, the criteria were the same as the first format, except that data for three cTnI measurement systems, which had data sets for less than eight cRMs (i.e., systems for which three or more of the cRMs did not yield results within the dynamic range for at least three of the four cTnI concentrations), were excluded. This was done in an attempt to eliminate possible bias attributable to measurement systems having a relatively limited analytical range. The third format included only data for cTnI systems yielding valid results for all four cTnI concentrations. The fourth format also included only data for which all four concentrations yielded valid cTnI measurements, except that data for the five cTnI measurement systems having data sets for less than six cRMs (i.e., systems for which five or more of the cRMs did not yield results within the dynamic range for all four cTnI concentrations) were excluded. This was also done in an attempt to eliminate possible bias attributable to measurement systems having a relatively limited analytical range.
In a fifth analysis format, the absolute deviation was used to rank the performance of each cRM within each cTnI system (as first, second, third, and so forth), according to the sum of absolute deviations from each set of cRMs. The criterion for incrementing the rank of a cRM within a cTnI system (i.e., from 1 to 2) was an increase in the sum of absolute deviation by either 0.1 or 1 SD, whichever was smaller. The cRMs were then ranked according to the means of their ranks across all cTnI systems. In addition, the number of times each material was ranked either first or second was recorded.
Linear regression analysis of cRM data. Least-squares linear regression analysis of cTnI results for each measurement system was carried out for each cRM according to the following:
Measured cTnI value ϭ (m ϫ cTnI expected value) ϩ b This linear regression method was used because it assigns all of the error to the dependent variable and, therefore, provides the most conservative estimate of error for the observed values. Regression parameters calculated included the slope, y-intercept, S y͉x , and correlation coefficient. Because of the large differences in the measured values among the cTnI systems, a relative S y͉x (S R y͉x ) was calculated by dividing the S y͉x by the mean of the measured values for that set of cRMs, and is expressed as a percentage as follows:
Results
The absolute deviation results for the first through the fourth data analysis formats are summarized in Tables 3  and 4 . As seen from Tables 3 and 4 , the cRMs designated E, B, G, and I (see Table 1 for identity) consistently showed favorable performance across the cTnI systems used as measurement tools, except I, which was the lyophilized version of the CI material from Spectral Diagnostics. The other three are all CTI complexes. The full sets of data used to develop Tables 3 and 4 are available as a data supplement to this article at Clinical Chemistry Online (http://www.clinchem.org/content/ vol47/issue3). Table 5 displays the performance of the cRMs within each cTnI measurement system as described for analysis format 5 in Materials and Methods. Materials E, B, D, and G showed the highest frequency of scoring top ranks among the various systems. (For the full data set used to develop Table 5 , see data supplement to this article at Clinical Chemistry Online, http://www.clinchem.org/content/ vol47/issue3).
The linear regression results for the cRMs are summarized in Tables 6 and 7 . Except for the slopes, materials B, G, E, and I showed overall satisfactory performance. Of note, the overall slopes for the cRMs showed a rather narrow range of 0.9342-1.0639, suggesting that recalibration with a common standard material could harmonize methods. The S R y͉x data displayed in Table 7 are particularly representative of overall performance because this term normalizes for differences between the measurement values for the cTnI systems. The full data set used to develop Tables 6 and 7 is available as a data supplement to this article at Clinical Chemistry Online (http://www. clinchem.org/content/vol47/issue3). Table 1 ) was ranked first or second among the cTnI systems used as measurement tools. Table 8 is a summary of the overall performance of the cRMs included in this analysis. The overall analysis indicated that cRM E showed the best overall performance, followed by cRMs B, G, and I.
Discussion
The primary objective of this cTnI Committee activity was to examine the analytic response of 13 cTnI measurement systems to the 10 cRMs that were characterized by NIST. It is important to note that this study was not designed to evaluate the accuracy of participating cTnI systems; rather, these cTnI systems were used as measurement tools to assess cRM performance. The three cRMs demonstrating the best overall performance consisted of the CTI complex; two were from Spectral Diagnostics, Inc., and one was from HyTest, Inc. The matrices of these materials differed, however; the CTI cRMs from Spectral Diagnostics were received in liquid form, but one was lyophilized by a third party and then reconstituted before distribution for this study. The cRM from HyTest was received in lyophilized form and then reconstituted before distribution. The cRM demonstrating the fourth best performance was a CI complex material received in lyophilized form and reconstituted before distribution.
In this study, the 10 g/L cTnI concentration for each cRM was used for normalization with the reasoning that imprecision of cTnI systems would most likely be satisfactory at this concentration. The 10 g/L concentration yielded results within the measurable ranges of all the cTnI methods for all cRMs. Use of the 10 g/L concentration allowed calculation of the absolute deviations used in formats 1-5 of the analyses. Different formats (2 and 4) were used to avoid bias that may have been present because of missing data. These analyses yielded similar results, indicating that the missing data had little impact on the final conclusions. Format 5 was performed to rank the consistency of each cRM within the cTnI measurement tools. Format 5 gave each cRM an ordinal rank within each cTnI method to avoid bias attributable to large differences between some of the assays. The mean rank of each cRM across the methods was used as rating criteria. As expected, the number of times the cRMs ranked first or second were closely paralleled with the mean rank.
As with all methods of analysis, there are strengths and caveats for assessing the various parameters from linear regression analysis. The slope and y-intercept clearly described the proportionality and limits between cRMs; however, the slope and y-intercept depend, in part, on calibration and are therefore not intrinsic characteristics of the antibodies used as reagents. The correlation coefficient showed a highly significant relationship between the cRMs and the calibrators of the manufacturers. However, all of the correlation coefficients were high, and therefore provided little discrimination. The S y͉x is representative of the SE at the mean of measurements, which can be difficult to interpret when comparing measurements that vary greatly in value. The relative S y͉x (S R y͉x ) corrects for the wide differences and was, therefore, better suited for a The comparative ranks for the cRMs were the same if results were within 1.0 of the cRM ranked next highest. The relative S yԽx (S R yԽx ) data for the cRMs, using the cTnI systems as the measurement tool, are represented as percentages, calculated by dividing the S yԽx by the average of the valid measurements for the cTnI systems. The ranks remained the same if the cRMs were within 1%. The analytical response for each cRM varied Ͼ40-fold for the 13 participating cTnI systems, underscoring the need for standardization. The differences in analytic response among cTnI systems, reflected by the mean absolute deviation values, were only 30 -50% for most of the cRMs (see Tables 3 and 4) . Furthermore, regression parameters and S R y͉x data from the linear regression analysis also indicated that better agreement between methods can be achieved via recalibration with a common standard. The slope and y-intercept data are not as informative because these two analytical parameters are associated with calibration and presumably can be adjusted or compensated for when an assay is recalibrated with a new reference material. This preliminary information offers the promise of producing reasonable harmony among cTnI measurement systems through the use of one of the cRMs as a reference material.
The overall outcome in this study, as indicated in Table  8 , is that the three cRMs composed of the CTI complex demonstrated the best performance. This finding is consistent with a recent study that showed a reduction in between-assay variability by calibration with a material composed of the CTI complex (15 ) . Of interest, two of the three cRMs were the same material with the only difference being lyophilization.
The cTnI Standardization Committee plans to use both serum pools and individual patient specimens to evaluate the ability of cRMs to reduce cTnI result variation across analytical systems. Evaluations of commutability of cRMs and other important characteristics are under consideration.
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